Abstract
Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have